MarketPulse

gene therapy

42 articles
The Motley FoolThe Motley Fool··Adria Cimino

CRISPR Therapeutics Poised for Growth on Casgevy Momentum and Pipeline Expansion

CRISPR Therapeutics eyes growth from Casgevy commercialization and pipeline expansion. FDA-approved gene therapy generates revenue while multiple clinical programs advance toward 2026 milestones.
VRTXCRSPFDA approvalclinical trials
The Motley FoolThe Motley Fool··Matthew Benjamin

Eli Lilly Acquires Orna Therapeutics for $2.4B to Expand Gene Therapy Pipeline

Eli Lilly acquires Orna Therapeutics for $2.4B to gain circular RNA gene therapy technology and autoimmune disease candidates, strengthening its pipeline.
MRKLLYacquisitionclinical trials